Excellos Launches to Accelerate Innovation in the Cell and Gene Therapy Industry
Retrieved on:
Tuesday, January 25, 2022
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Celler, Drug development, Acquisition, Therapy, THP, Industry, CA, Patient, VP, Life, TILS, Head, Collection, Research, CGMP, Business development, CEO, Science, Tissue, CSO, Mobile phone, Fine chemical, Excellos, Telegraph Hill Partners, EXCELLOS, TELEGRAPH HILL PARTNERS
Excellos will create highly characterized, standardized cell products and custom services that are essential for advanced therapeutics, said David Wellis Ph.D., CEO of Excellos.
Key Points:
- Excellos will create highly characterized, standardized cell products and custom services that are essential for advanced therapeutics, said David Wellis Ph.D., CEO of Excellos.
- Chief Commercial Officer George Eastwood, brings significant experience in the cell and gene therapy space, with a focus on cGMP materials and cell manufacturing.
- Most recently, as CSO of SDBB, he led the cell therapy, immunohematology, components manufacturing, and cord blood banking labs.
- Excellos is dedicated to improving human life by providing critical products and services to life science research and the next generation of cell and gene therapies.